- Home
- IPHA vs BMN Comparison
IPHA vs BMN Comparison
Compare IPHA & BMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- BMN
- Stock Information
- Founded
- IPHA 1999
- BMN 2020
- Country
- IPHA France
- BMN United States
- Employees
- IPHA N/A
- BMN 19800
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- BMN Trusts Except Educational Religious and Charitable
- Sector
- IPHA Health Care
- BMN Finance
- Exchange
- IPHA Nasdaq
- BMN Nasdaq
- Market Cap
- IPHA 160.1M
- BMN 146.9M
- IPO Year
- IPHA 2019
- BMN N/A
- Fundamental
- Price
- IPHA $2.18
- BMN $24.33
- Analyst Decision
- IPHA Strong Buy
- BMN
- Analyst Count
- IPHA 1
- BMN 0
- Target Price
- IPHA $11.00
- BMN N/A
- AVG Volume (30 Days)
- IPHA 28.8K
- BMN 29.9K
- Earning Date
- IPHA 03-27-2025
- BMN 01-01-0001
- Dividend Yield
- IPHA N/A
- BMN 4.66%
- EPS Growth
- IPHA N/A
- BMN N/A
- EPS
- IPHA N/A
- BMN N/A
- Revenue
- IPHA $20,831,349.00
- BMN N/A
- Revenue This Year
- IPHA $209.83
- BMN N/A
- Revenue Next Year
- IPHA $83.15
- BMN N/A
- P/E Ratio
- IPHA N/A
- BMN N/A
- Revenue Growth
- IPHA N/A
- BMN N/A
- 52 Week Low
- IPHA $1.29
- BMN $21.51
- 52 Week High
- IPHA $3.51
- BMN $25.59
- Technical
- Relative Strength Index (RSI)
- IPHA 53.46
- BMN 51.61
- Support Level
- IPHA $2.06
- BMN $23.97
- Resistance Level
- IPHA $2.24
- BMN $24.33
- Average True Range (ATR)
- IPHA 0.09
- BMN 0.36
- MACD
- IPHA -0.01
- BMN 0.03
- Stochastic Oscillator
- IPHA 53.33
- BMN 34.94
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.